"pharmaceutical-sector"

Anthem Biosciences shares debuted with a 27% premium over the IPO price of ₹570, listing at ₹723 on Monday. The ₹3,395-crore IPO, subscribed 63.86 times, saw strong institutional interest. Anthem is a CRDMO specializing in complex fermentation-based APIs

Warns that Indian pharmaceutical products could become more expensive in the US, reducing their competitiveness in one of the world's largest markets

Plans to commence operations by the end of the current fiscal.

KTR writes to Union Minister to allocate Rs 870 cr for 2021-22 fiscal against Central funding of Rs 4,922 cr

Developments on vaccine front offer a tentative timeline on when it could be available on a mass scale